Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
PT Organon Pharma Indonesia Tbk
SCPI
Sector: Healthcare
Industry: Pharmaceuticals
Sub Sector: Pharmaceuticals & Health Care Research
Sub Industry: Pharmaceuticals
Live quote
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
96.026
ROE
22,99%
ROA
18,75%
Book Value
417.729
Net Income
172,85 M
Total Sales
1,64 T
Total Assets
1,84 T
DER
0.23x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
1,21%
ORGANON LLC 🔗
98,79%
Corporate · Asing
Tentang Perusahaan
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Produk & Lini Bisnis
The scope of the Company activities is processing, packaging and developing pharmaceutical products for human and animal consumption, toiletries, cosmetics, household and related products.
Dewan Direksi
D
Daniel
President Director
Y
Yuliana
Director
AS
Andri Soelastyo
Director
YX
Yeap Xin Yi
Director
Dewan Komisaris
AD
Andreas Daugaard Jorgensen
President Commissioner
EA
Erwin Agung
Commissioner
GA
Gideon Adi Siallagan
Independent Commissioner
Anak Usaha & Afiliasi
NamaDomisili%
 %
Trend Keuangan (5 periode terakhir) — hover bar untuk detail
Total Sales Net Income (+) Net Income (-)
4,1M 3,1M 2,1M 1,0M 0 Sales 2025Q2: Rp 1.733.566.957 Net Income 2025Q2: Rp 131.693.264 2025Q2 Sales 2025Q3: Rp 2.907.780.868 Net Income 2025Q3: Rp 237.985.070 2025Q3 Sales 2025Q4: Rp 4.122.385.016 Net Income 2025Q4: Rp 290.705.632 2025Q4 Sales 2026Q1: Rp 863.806.318 Net Income 2026Q1: Rp 86.244.066 2026Q1 Sales 2026Q2: Rp 1.644.787.548 Net Income 2026Q2: Rp 172.846.422 2026Q2
2025 Q2
EPS 73.163
ROE 22,61%
2025 Q3
EPS 88.143
ROE 24,97%
2025 Q4
EPS 80.752
ROE 21,84%
2026 Q1
EPS 95.827
ROE 24,34%
2026 Q2
EPS 96.026
ROE 22,99%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
PeriodeTotal SalesNet IncomeTotal AssetsTotal EquityEPSROEDER
2026 Q2 1,64 T 172,85 M 1,84 T 1,50 T 96.026 22,99% 0.23x
2026 Q1 863,81 M 86,24 M 2,23 T 1,42 T 95.827 24,34% 0.58x
2025 Q4 4,12 T 290,71 M 2,28 T 1,33 T 80.752 21,84% 0.71x
2025 Q3 2,91 T 237,99 M 2,14 T 1,27 T 88.143 24,97% 0.68x
2025 Q2 1,73 T 131,69 M 1,91 T 1,16 T 73.163 22,61% 0.64x
Trend Harga Penutupan & Book Value — hover titik untuk detail
Close Price Book Value
456,6K 344,8K 233,1K 121,3K 9,6K Book Value 2025Q2: Rp 323.527 Close 2025Q2: Rp 29.000 2025Q2 Book Value 2025Q3: Rp 353.053 Close 2025Q3: Rp 29.000 2025Q3 Book Value 2025Q4: Rp 369.716 Close 2025Q4: Rp 29.000 2025Q4 Book Value 2026Q1: Rp 393.673 Close 2026Q1: Rp 29.000 2026Q1 Book Value 2026Q2: Rp 417.729 Close 2026Q2: Rp 29.000 2026Q2
2025 Q2
Close 29.000
BV 323.527
ROA 13,76%
2025 Q3
Close 29.000
BV 353.053
ROA 14,82%
2025 Q4
Close 29.000
BV 369.716
ROA 12,77%
2026 Q1
Close 29.000
BV 393.673
ROA 15,44%
2026 Q2
Close 29.000
BV 417.729
ROA 18,75%
History Harga Penutupan & Book Value
TahunQrtClose Price (Rp)Book Value (Rp)ROA
2026 2 29.000 417.729 18,75%
2026 1 29.000 393.673 15,44%
2025 4 29.000 369.716 12,77%
2025 3 29.000 353.053 14,82%
2025 2 29.000 323.527 13,76%
Data diperbarui pada: 2026-05-12 11:51:58